BioArctic AB Series B
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more
BioArctic AB Series B (0RV2) - Total Liabilities
Latest total liabilities as of December 2021: Skr109.05 Million SEK
Based on the latest financial reports, BioArctic AB Series B (0RV2) has total liabilities worth Skr109.05 Million SEK as of December 2021.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioArctic AB Series B - Total Liabilities Trend (2017–2021)
This chart illustrates how BioArctic AB Series B's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioArctic AB Series B Competitors by Total Liabilities
The table below lists competitors of BioArctic AB Series B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Radius Recycling, Inc.
NASDAQ:RDUS
|
USA | $944.09 Million |
|
Pasifik Eurasia Lojistik Dis Ticaret A.S.
IS:PASEU
|
Turkey | TL846.88 Million |
|
S N Nuclearele
RO:SNN
|
Romania | RON1.73 Billion |
|
Adaro Minerals Indonesia Tbk PT
JK:ADMR
|
Indonesia | Rp891.42 Million |
|
CGN Mining Company Limited
PINK:CGNMF
|
USA | $4.71 Billion |
|
Baosheng
SHG:600973
|
China | CN¥17.32 Billion |
|
Técnicas Reunidas S.A
PINK:TNISF
|
USA | $5.23 Billion |
|
Amore Group
KO:002790
|
Korea | ₩1.39 Trillion |
Liability Composition Analysis (2017–2021)
This chart breaks down BioArctic AB Series B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioArctic AB Series B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioArctic AB Series B (2017–2021)
The table below shows the annual total liabilities of BioArctic AB Series B from 2017 to 2021.
| Year | Total Liabilities | Change |
|---|---|---|
| 2021-12-31 | Skr109.05 Million | -23.75% |
| 2020-12-31 | Skr143.01 Million | -31.52% |
| 2019-12-31 | Skr208.84 Million | -44.36% |
| 2018-12-31 | Skr375.31 Million | -25.59% |
| 2017-12-31 | Skr504.35 Million | -- |